Researchers at the UCLA Jonsson Comprehensive Cancer Center have found that a virus-mimicking drug, BO-112, may also make certain stealthy melanoma tumors visible to the immune system, allowing them to be better targeted by immunotherapy.
Richard Pazdur, founding director of FDA’s Oncology Center of Excellence and long-time FDA visionary, has accepted the top job at FDA’s Center for Drug Evaluation and Research following George F. Tidmarsh’s dramatic ouster from the position.
